Thermo Fisher Scientific Inc. $TMO Stock Position Increased by Candriam S.C.A.

Key Points

• Candriam S.C.A. increased its stake in Thermo Fisher Scientific Inc. by 3.6% in the first quarter, now owning 422,354 shares valued at approximately $210 million.
• CEO Marc N. Casper recently sold 10,000 shares of the company for over $4.5 million, marking a 7.99% decrease in his ownership.
• Equities analysts have set new price targets for Thermo Fisher Scientific, with Goldman Sachs recommending a $610.00 target, indicating strong growth expectations for the stock.

Candriam S.C.A. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 422,354 shares of the medical research company's stock after purchasing an additional 14,864 shares during the quarter. Thermo Fisher Scientific comprises about 1.3% of Candriam S.C.A.'s portfolio, making the stock its 10th biggest holding. Candriam S.C.A. owned approximately 0.11% of Thermo Fisher Scientific worth $210,164,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Port Capital LLC increased its position in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after acquiring an additional 22 shares during the last quarter. Clark Capital Management Group Inc. increased its position in shares of Thermo Fisher Scientific by 0.5% during the fourth quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after acquiring an additional 23 shares during the last quarter. Monograph Wealth Advisors LLC increased its position in shares of Thermo Fisher Scientific by 0.3% during the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after acquiring an additional 23 shares during the last quarter. Finally, Intergy Private Wealth LLC increased its position in shares of Thermo Fisher Scientific by 5.8% during the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after acquiring an additional 23 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 295 shares of the business's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total value of $147,511.80. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,591,606.96. This trade represents a 0.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,896 shares of company stock valued at $8,593,838 in the last three months. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently commented on TMO shares. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. UBS Group increased their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Finally, Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $16.4780 during trading hours on Friday, reaching $500.2380. The company had a trading volume of 1,778,365 shares, compared to its average volume of 2,406,376. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The business has a fifty day simple moving average of $443.02 and a 200 day simple moving average of $457.46. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $188.89 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company earned $5.37 earnings per share. The business's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.